Prognostic Factors of Patients With ADHF
Elevated Blood Monocyte Count Predicts 1 Year Poor Outcomes for Patients Admitted With Acute Decompensated Heart Failure
1 other identifier
observational
362
0 countries
N/A
Brief Summary
To explore the prognostic indicators for patients with ADHF
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 2, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2015
CompletedFirst Submitted
Initial submission to the registry
May 4, 2020
CompletedFirst Posted
Study publicly available on registry
May 18, 2020
CompletedMay 18, 2020
May 1, 2020
3.5 years
May 4, 2020
May 13, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
all-cause death
The primary end point was one-year all-cause death
1 year
Secondary Outcomes (1)
HF-related rehospitalization
1 year
Study Arms (2)
high group
high group: monocyte count≥0.445×10\*9 cells/L
low group
low group: monocyte count\<0.445×10\*9 cells/L;
Interventions
The monocyte count at admission was higher than 0.445×10\*9 cells/L
Eligibility Criteria
ADHF patient diagnosed in the department of cardiovascular medicine in the first affiliated hospital of chongqing medical university
You may qualify if:
- Patients with ADHF diagnosed according to ESC Guidelines for the diagnosis of acute heart failure 2008
You may not qualify if:
- disorders of the hematopoietic system, history of cancer and/or previous treatment with chemotherapy, the infection caused by various pathogens, chronic inflammatory conditions, glucocorticoid therapy and/or histories of glucocorticoid use 3 months before the admission and acute myocardial infarction or coronary revascularization within the past 6 months. Also, patients who did not have a differential WBC count or who were lost to follow-up were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
May 4, 2020
First Posted
May 18, 2020
Study Start
August 2, 2011
Primary Completion
February 16, 2015
Study Completion
February 16, 2015
Last Updated
May 18, 2020
Record last verified: 2020-05